Maxim Reiterates Buy On OncoSec Medical Following F1Q15 Update
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on OncoSec Medical (OTC:ONCS) with a $3.00 price target, as the company reported fiscal first-quarter results, posting $4.1M loss and $34M in cash. The company should be funded through the next 12 months, according to the analyst.
Kolbert noted, “While OncoSec’s clinical stage is early, the data continue to be impressive. We apply a high-risk discount rate of 30% in our modeling assumptions. Using these metrics, we model the market potential and discount back in our FCF, discounted-EPS, and sum-of-the-parts models to arrive at a $3.00 price target.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 6.2% and a 44.4% success rate. Kolbert has a 6.2% average return when recommending ONCS, and is ranked #551 out of 3398 analysts.